Uniqure (NASDAQ:QURE) specializes in the development of gene therapies, aiming to deliver transformative treatments for patients suffering from rare diseases. The company leverages its modular platform to address various genetic disorders, with a sharp focus on hemophilia, Huntington's disease, and congestive heart failure. Uniqure's pipeline includes several innovative gene therapy projects in different stages of development, from preclinical studies to late-stage clinical trials. The objective of Uniqure is to pioneer sustainable gene therapies that offer long-lasting benefits to patients with the least amount of treatment-related burden, ultimately improving the quality of life for those affected by challenging genetic conditions. Through its research and development efforts, Uniqure is committed to leading the way in the field of gene therapy and bringing hope to individuals and families impacted by rare diseases.